Myriad, Rival Strike Deal In Cancer-Test Patent Dispute

Law360, Los Angeles (February 7, 2014, 3:43 PM EST) -- Myriad Genetics Inc. has settled its suit against Gene by Gene Ltd. over alleged infringement of its cancer-testing patents, including several that were upheld in a landmark U.S. Supreme Court decision last year, with Gene by Gene agreeing to stop offering the tests in North America, the companies said Friday.

Myriad agreed to drop claims that Houston-based Gene by Gene's genetic testing infringed nine of its patents, according to a joint statement by the companies. In return, Gene by Gene said it would stop selling and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.